Experimental group:apatinib

5 trials

Conditions

Cholangiocarcinomacervical carcinomahepatocellular carcinoma, HCCrecurrent / metastatic head and neck squamous cell carcinomatumors of the biliary tract

Early Phase 1

Efficacy and safety of apatinib in the maintenance therapy after concurrent chemoradiotherapy in the treatment of IIIc-IVa phase cervical cancer with complete remission at the first time measurement

RecruitingChiCTR2000028797

Shandong Institute of Cancer Prevention and Controlcervical carcinoma

Start: 2019-11-01Updated: 2020-01-06

Phase 2

Apatinib in patients with first-line chemotherapy-refractory recurrent or metastatic cholangiocarcinoma: a phase 2, single-arm, prospective study

RecruitingChiCTR2100046565

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityCholangiocarcinoma

Start: 2021-06-01Updated: 2022-01-04

Phase 4

A prospective randomized controlled trial of Apatinib or S-1 or Capecitabine as Maintence Trerapy after radical correction of tumors of the biliary tract

RecruitingChiCTR1800015601

JIANGSU HENGRUI MEDICINE CO., LTD.tumors of the biliary tract

Start: 2018-05-01Updated: 2018-04-30

Exploratory study on the combination of Adebrelimab and Apatinib in the treatment of PD-1 inhibitor induced liver cancer

Active, not recruitingChiCTR2400087077

Shandong First Medical University Affiliated Cancer Hospitalhepatocellular carcinoma, HCC

Start: 2024-07-31Updated: 2024-07-22

Unknown Phase

The prospective, open, multi-center clinical study of Apatinib(Aitan) in non-first-line treating patient with recurrent/metastatic head and neck squamous cell carcinoma

Active, not recruitingChiCTR-OOC-16008751

The fourth affiliated hospital of Guangxi Medical Universityrecurrent / metastatic head and neck squamous cell carcinoma

Start: 2016-08-01Updated: 2017-04-18

Experimental group:apatinib

Sponsors

Conditions

Early Phase 1

Phase 2

Phase 4

Unknown Phase